OPKO Health Announces $100 Million Share Repurchase Program
July 18, 2024 08:00 ET
|
OPKO Health, Inc.
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's...
OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments
July 17, 2024 16:14 ET
|
OPKO Health, Inc.
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by...
OPKO Health to Participate in the Jefferies Global Healthcare Conference
May 31, 2024 10:48 ET
|
OPKO Health, Inc.
MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024...
OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
May 07, 2024 16:05 ET
|
OPKO Health, Inc.
MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business...
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
May 03, 2024 08:00 ET
|
OPKO Health, Inc.
MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S....
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
March 05, 2024 08:52 ET
|
OPKO Health, Inc.
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal...
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
February 27, 2024 16:05 ET
|
OPKO Health, Inc.
MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights...
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
February 22, 2024 16:05 ET
|
OPKO Health, Inc.
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the...
OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes
January 09, 2024 16:05 ET
|
OPKO Health, Inc.
MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the closing of its previously announced private offering of $230.0 million aggregate...
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 08:00 ET
|
OPKO Health, Inc.
MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held...